Friday, March 14, 2025 8:29:48 PM
dennisdave,
Flaskworks is not an end to end processor and Sawston will be majority fitted out with Flaskworks not artisan with an import/export license so no need to think artisan space will not be eventually converted or utilized for other product development from other customers. The clean rooms needed for Flaskworks are a step down from those used for artisan method and are much less expensive to maintain. The new smaller footprint Flaskworks design should expand capacity beyond that already mentioned too. Initiating with the UK with capacity to expand from there into other indications or cover initial EU capacity and utilizing Sawston as a training center for expansion makes sense to me as there would be a centralized training center campus where patients are actually receiving treatments instead of something set up at remote sites with need for more travel time and less actual production being done with said employees. Best wishes.
Flaskworks is not an end to end processor and Sawston will be majority fitted out with Flaskworks not artisan with an import/export license so no need to think artisan space will not be eventually converted or utilized for other product development from other customers. The clean rooms needed for Flaskworks are a step down from those used for artisan method and are much less expensive to maintain. The new smaller footprint Flaskworks design should expand capacity beyond that already mentioned too. Initiating with the UK with capacity to expand from there into other indications or cover initial EU capacity and utilizing Sawston as a training center for expansion makes sense to me as there would be a centralized training center campus where patients are actually receiving treatments instead of something set up at remote sites with need for more travel time and less actual production being done with said employees. Best wishes.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
